RGCC Baseline and Follow-Up Tests:

OncoTrace:

• Used as a BASELINE and FOLLOW-UP tool to determine starting point, and monitoring effectiveness oftreatment protocols
• May also be used for long-term monitoring following successful treatment for early detection of recurrence
• Detects presence of ALL cancer types (except those of CNS origin)
• Detects the presences and number of CTCs in the blood (circulating tumor cells)
• Detects phenotype markers to determine tissue origin
• Detects Stemness Markers to monitor activity level of the CTCs to determine prognosis (potential for the cancer to proliferate (be aggressive), metastasize, resist treatment, or recur) and to determine when care is done
• For hematologic (blood) & solid tumors
• Sample Type: Blood

OncoTrail:

• Use when you know the primary origin of the tumor for specific cancer types only (see list below)
• Used as a BASELINE and FOLLOW-UP tool to determine starting point, and monitoring effectiveness of treatment protocols.
• More suitable as a FOLLOW-UP tool following the OncoTrace once it is determined no secondary cancer is present
• Contains more biomarkers than OncoTrace for the specific type of cancer
  • Breast
  • Colon
  • GI
  • Lung
  • Melanoma
  • Prostate
  • Sarcoma
• May also be used for long-term monitoring following successful treatment for early detection of recurrence
• Detects the presences and number of CTCs in the blood (circulating tumor cells)
• Detects phenotype markers to confirm known tissue origin
• Detects Stemness Markers to monitor activity level of the CTCs to determine prognosis (potential for the cancer to proliferate (be aggressive), metastasize, resist treatment, or recur) and to determine when care is done
• For hematologic (blood) & solid tumors
• Sample Type: Blood

OncoCount:

• Used as a FOLLOW-UP tool for monitoring effectiveness of treatment protocols
• Detects presence of ALL cancer types (except those of CNS origin)
• Detects the presence and number of CTCs in the blood (circulating tumor cells)
• For hematologic (blood) & solid tumors
• Sample Type: Blood

RGCC Treatment Protocol Tests

Onconomics Plus:

• Most comprehensive individualized profile available (preferred for all baseline testing)
• Combination of Onconomics and Onconomics Extracts Panels
• Includes chemosensitivity testing of both chemotherapeutic agents AND natural substances
• Answers the question: “Which are the most effective chemotherapeutic agents and natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does OncoTrace and OncoTrail)
• Detects validated tumor-related Genetic and Physiological expressions used for customization of treatment protocols
• Includes Resistance Factors to further refine timing and rotation of treatment protocols
• Includes Chemosensitivity (Pharmacodynamic) testing to determine the effectiveness of 53 Chemotherapeutic agents + 60 targeted drugs + 53 natural substances + 5 additional substances upon request at no additional cost
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Onconomics:

• Comprehensive, individualized profile
• Answers the question: “Which are the most effective chemotherapeutic agents?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does OncoTrace and OncoTrail)
• Detects validated tumor-related Genetic and Physiological expressions used for customization of treatment protocols
• Includes Resistance Factors to further refine timing and rotation of treatment protocols
• Includes Chemosensitivity (Pharmacodynamic) testing to determine the effectiveness of 53 Chemotherapeutic agents + 60 targeted drugs + 5 additional substances upon request at no additional cost
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Onconomics Extracts+:

• Comprehensive, individualized profile
• Answers the question: “Which are the most effective natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does OncoTrace and OncoTrail)
• Detects validated tumor-related Genetic and Physiological expressions used for customization of treatment protocols
• Includes Resistance Factors to further refine timing and rotation of treatment protocols
• Includes Chemosensitivity (Pharmacodynamic) testing to determine the effectiveness of 53 natural substances + 5 additional substances upon request at no additional cost
• Anti-Cancer effect measured by studying:
  • Inhibition of - Signaling Transduction Pathways, Growth Factor Receptors, and Angiogenesis Receptors
  • Immunostimulation/Immunomodulation - Release of Cytokines and increase of PBMC & NK cells
  • Cytotoxic Effect – Activation of Caspase and Cytochrome C
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Onconomics Extracts:

• Individualized profile showing the efficacy of treatment using natural substances
• Answers the question: “Which are the most effective natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does OncoTrace
  and OncoTrail)
• Includes testing of 53 natural substances + 5 additional substances upon request at no additional cost
• Anti-Cancer effect measured by studying:
• Inhibition of - Signaling Transduction Pathways, Growth Factor Receptors, and Angiogenesis Receptors
• Immunostimulation/Immunomodulation - Release of Cytokines and increase of PBMC & NK cells
• Cytotoxic Effect – Activation of Caspase and Cytochrome C
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Immune Frame:

• When you need to evaluate the immune status of the patient to determine eligibility for use of Cellular
  Therapies. It is also used for establishing a baseline and monitoring therapeutic response.
• Prerequisite for RGCC Cellular Therapies
• Important for treatment algorithm to determine which therapy is appropriate for the patient
• Determination of:
  • Cachexia (a.k.a. Wasting Syndrome) - A general state of ill health involving marked weight loss and
    muscle loss.
  • Presence and stimulation of DC’s (dendritic cells)
  • Specific Humoral and Cellular Immunity
  • Non-specific Cellular Immunity
  • Immunosuppressive Mechanisms
  • Activation of T and B Memory cells for long-term immunity

RGCC Advanced Diagnostic Tests:

aCGH

• Use when you don’t know the primary origin of the tumor
• Detects abnormalities that may be associated with the primary tumor
• For hematologic (blood) & solid tumors
• Sample Type: Blood

ChemoSNiP:

• Pharmacokinetics (how body metabolizes drugs)
• Examines inherited variations in genes that dictate drug response and explores the way these variations can be used to predict whether a patient will have a good response to a drug, a bad response, or no response at all.
• When used together with data from chemosensitivity testing, it helps to narrow the selection to the most effective and least toxic therapeutic agent.
• Sample Type: Blood or Swab

Metastat:

• Advanced test to detect blood born markers that can accurately determine whether a secondary tumor is likely
  to develop and its likely location
• Potential Sites of Metastasis:
  • General
  • Lung
  • Brain
  • Liver
  • Bones

CAMBISeq:

• Cancer Analysis Mutational Burden Instability Sequencing
• Technique: NGS (Next Generation Sequencing)
• Identifies beneficial mutations for cancer treatment (FDA approved treatments only)
• The higher the number of mutations, the better the outcome for the patient
• Analyze mutational profile of CTCs
• DNA & RNA is studies to detect splice variants
• High Coverage = means the test is able to detect very rare mutations
• Typically used in medical oncology after first-line therapies have been exhausted to determine if there are any
  immunotherapy, targeted therapies, or clinical trials available as additional treatment options
• Predicts efficacy of immunotherapy or targeted therapy